Metformin / Vildagliptin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), SMC (Scotland) and TLV (Sweden) recommended or restricted metformin / vildagliptin, while AWMSG (Wales) did not recommend it.
Where metformin / vildagliptin met resistance it was usually narrowed rather than refused: 2 of 5 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 6.8 years, from 7 Jul 2008 at SMC (Scotland) to 20 May 2015 at HAS (France).
TLV (Sweden) changed its position: recommended on 26 Sep 2008, restricted by 1 Dec 2009.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for metformin / vildagliptin, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2015; on this evidence the file is dormant.
3 distinct indication wordings are recorded for metformin / vildagliptin by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess metformin / vildagliptin, on 7 Jul 2008; HAS (France) did not open a file until 29 Oct 2014 — a wide spread of 6.2 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
Restriction is doing real work here: 2 of 5 decisive outcomes narrowed metformin / vildagliptin to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
3 of the 5 agencies here assessed metformin / vildagliptin more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed metformin / vildagliptin.
The full ledger for metformin / vildagliptin reads 2 recommended, 2 other, 2 restricted and 1 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 20 May 2015 | Listing renewal (Transparency Committee) | SMR moderate | source |
| G-BA (Germany) | 1 Oct 2013 | Zomarist — benefit assessment §35a | added benefit: not proven | source |
| SMC (Scotland) | 13 May 2013 | Treatment of type 2 diabetes mellitus: in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately c… | not recommended | source |
| AWMSG (Wales) | 22 Mar 2013 | for the treatment of type 2 diabetes mellitus in combination with a sulphonylurea (i.e. triple combination therapy) as a… | not endorsed (non-submission) | source |
| TLV (Sweden) | 1 Dec 2009 | Vi beslutar att Eucreas ska ingå i högkostnadsskyddet med begränsning | restricted subsidy | source |
4 further decisions for metformin / vildagliptin, across 3 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- empagliflozin — same ATC class A10B — Diabetes
- dapagliflozin — same ATC class A10B — Diabetes
- semaglutide — same ATC class A10B — Diabetes
- metformin / sitagliptin — same ATC class A10B — Diabetes
- liraglutide — same ATC class A10B — Diabetes
- sitagliptin — same ATC class A10B — Diabetes
Coverage: 9 decisions for metformin / vildagliptin from 5 agencies, 2008 to 2015. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.